Between 1959 and 1985, at least 1,848 children in the United Kingdom were injected with growth hormone extracted from the pituitary glands of people who had died. It worked. It also carried something nobody was looking for: worldwide, more than 200 recipients later developed iatrogenic Creutzfeldt-Jakob disease, 80 of them in the UK, figures set out by the UCL Prion Unit team in Nature Medicine in January 2024. The material was withdrawn in the mid-1980s and replaced by synthetic hormone. What the same team has been asking since is whether the prions were the only passenger.

On 30 March 2026, JAMA Neurology published their answer so far, and it is a small one. Gargi Banerjee, Simon Mead, John Collinge and colleagues report a case series of four men (JAMA Neurol. 2026;83(5):435-441). All had confirmed or suspected childhood treatment with cadaveric pituitary-derived human growth hormone; all developed dementia, with symptom onset between the ages of 47 and 60; all were among 14 recipients referred to the UK National Prion Clinic between February 2024 and February 2025, with the data analysed in February and March 2025. In each case the cognitive syndrome was led not by memory loss but by language, a pattern the authors note could be mistaken for the frontotemporal dementia spectrum. One of the four had died, and it is his postmortem examination, at 57, ten years after his symptoms began, that gives the paper its title: extensive amyloid-beta in the brain tissue, severe and widespread cerebral amyloid angiopathy, and extensive tau, together corresponding to the highest level of Alzheimer's disease neuropathological change, including severe tauopathy.

That matters because the 2024 paper, which described eight recipients of whom five had been referred with early-onset dementia, rested on clinical picture and biomarkers rather than tissue. Critics went straight for that gap: in Alzheimer's and Dementia in July 2024, Lea Grinberg and Ellen Leschek argued the published cases did not meet the diagnostic bar for Alzheimer's disease and that alternative explanations existed. A single autopsy does not settle an argument about causation, but it does close one line of retreat. In the linked JAMA Neurology editorial, Brian Appleby and Mark Cohen of Case Western Reserve University, both of the Cleveland Alzheimer's Disease Research Center, called it "the strongest confirmation of an AD diagnosis in their cohort" while holding the line that the evidence to date supports iatrogenic transmission of amyloid-beta rather than of Alzheimer's disease itself, and that definitive causation may stay out of reach in so heterogeneous a group.

Here is the sentence a family should hold onto, and it comes from the editorialists rather than from us: nothing in these cases suggests that Alzheimer's disease is contagious, or transmissible in any current medical scenario. The proposed route is specific and closed. It runs through a discontinued product made by pooling glands from many donors, injected repeatedly into children, with a latency measured in decades. No case here involves living together, caring for someone, kissing them, or sharing a household. Nor is the picture uniform across countries: a 2013 JAMA Neurology analysis of recipients from the US National Hormone and Pituitary Program identified no Alzheimer's or Parkinson's deaths at all, despite that population's markedly raised risk of prion disease.

What is genuinely new sits in the tissue and in the clinic. For neuropathology, it is the first autopsy in this cohort showing full-house Alzheimer's change rather than amyloid deposits alone, which is why the seeding hypothesis, that misfolded amyloid-beta can act as a template and, given thirty or forty years, pull a brain into the Alzheimer's process, is now harder to wave away. For clinicians, the practical point is duller and more useful: a man in his late forties whose language goes first, with a childhood history of cadaveric growth hormone, deserves amyloid and tau testing rather than an assumption of frontotemporal dementia. Appleby and Cohen say plainly that recipients worried about their memory or their words should be formally assessed for Alzheimer's disease and for everything else that causes cognitive decline. That is a conversation with a neurologist, not a conclusion to be drawn at home.